Form 4: ALX Oncology CEO Jason Lettmann Acquires 42,000 Shares Following Positive Clinical Trial Results

ALX Oncology's CEO, Jason Lettmann, acquired 42,000 shares of common stock on March 14, 2025, following the achievement of performance metrics related to positive results from the ASPEN-06 clinical trials.

Summary

• On March 14, 2025, Jason Lettmann, CEO of ALX Oncology Holdings Inc., acquired 42,000 shares of common stock.
• The acquisition was a result of achieving certain performance metrics tied to the positive results of the ASPEN-06 clinical trials.
• These shares are represented by performance share units (PSUs) and vest on March 14, 2026.
• Following the transaction, Lettmann directly owns 212,270 shares of ALX Oncology.
• The transaction was reported on March 18, 2025.

Sentiment

Score: 8

Explanation: The acquisition of shares by the CEO following positive clinical trial results is a positive signal, indicating confidence in the company's future performance. The vesting schedule also aligns management's interests with long-term shareholder value.

Positives

• The acquisition of shares by the CEO signals confidence in the company's performance and future prospects.
• Achievement of performance metrics related to the ASPEN-06 clinical trials indicates positive progress in ALX Oncology's clinical development programs.
• The vesting of PSUs on March 14, 2026, aligns management's interests with long-term shareholder value.

Future Outlook

The vesting of the performance share units in 2026 suggests a continued focus on achieving long-term performance goals related to clinical trial outcomes.

Industry Context

This announcement reflects the common practice of aligning executive compensation with company performance, particularly in the biotechnology industry where clinical trial results are critical milestones.

Stakeholder Impact

• Shareholders may view the CEO's share acquisition as a positive sign of confidence in the company's future prospects.
• Employees may be motivated by the achievement of performance metrics and the alignment of management's interests with company success.

Key Dates